Therapeutic Effects and Effects on Body Fat of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes for 1-4 Years

Inclusion Criteria:

1. Diagnosed type 2 diabetes according to the 1999 WHO standards;
2. received at least 8 weeks of simple diet control and physical exercise beforescreening; Patients with type 2 diabetes who were treated with stable hypoglycemicdrugs and had inadequate glycemic control within 8 weeks prior to screening;
3. HbA1c≥7.5%；
4. BMI>24kg/m2;
5. Subjects agree to maintain a scientific diet and exercise habits throughout the study,and regularly self-monitor and record blood sugar (SMBG);
6. Be willing to sign written informed consent and comply with the study protocol

Exclusion Criteria:

1. Use of any of the following drugs or treatments in the 3 months prior to screening:treatment with GLP-1RA, GLP-1 analogue, DPP-4 inhibitor, or any other incretinanalogue;
2. Long-term (more than 7 consecutive days) intravenous administration, oraladministration, or intra-articular administration of corticosteroids within 2 monthsprior to screening;
3. Use of weight control drugs or surgery that can lead to weight instability within 2months before screening, or are currently in a weight loss program and not in themaintenance stage:
4. History of acute and chronic pancreatitis; A history of medullary C-cell carcinoma,MEN (multiple endocrine tumors) 2A or 2B syndrome, or related family history;
5. Clinically significant gastric emptying abnormalities;
6. tumors of any organ system that have been treated or not treated in the 5 years priorto screening;
7. had received coronary angioplasty, coronary stenting, or coronary artery bypass within 6 months before screening. Negligent compensatory heart failure (NYHA rating III andIV), stroke or transient ischemic attack, unstable angina, myocardial infarction,persistent and clinically significant arrhythmia;
8. Acute metabolic complications occurred within 6 months before screening;
9. Before screening, any of the laboratory test indicators meet the following criteria:glutamic-pyrugenic transaminase >2.5 times or ASpartate transaminase >2.5 times; eGFR <45ml/min/1.73m2; Fasting glycerin tricol >5.64mmol/L.